



Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference

2025-11-12

LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025 at 8:00 a.m. ET (1:00 p.m. GMT).

The live webcast can be accessed in the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available following the conference.

About Silence Therapeutics

Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNAs designed to precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence focuses on areas of high unmet medical need with programs advancing in cardiovascular disease, hematology and rare diseases. For more information, please visit <https://www.silence-therapeutics.com/>.

View source version on **businesswire.com**: <https://www.businesswire.com/news/home/20251112215352/en/>

Inquiries:

Silence Therapeutics plc
Gem Hopkins, VP, Head of IR and Corporate Communications
ir@silence-therapeutics.com

Tel: +1 (646) 637-3208

Source: Silence Therapeutics plc